Investing.com -- HistoSonics Inc., a medical device firm backed by Johnson & Johnson (NYSE: JNJ )'s venture capital division, is contemplating a US initial public offering (IPO) that could take place within the year, according to a Monday report by Reuters. The company is in talks with investment banks and is considering a share sale that could potentially generate several hundred million dollars.

According to the report, HistoSonics could seek a valuation in the billions of dollars for the listing. The company reportedly is still in the early stages of deliberations and no final decisions have been made yet.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.